Vaccinex Inc. (VCNX)
Vaccinex Statistics
Share Statistics
Vaccinex has 2.68M shares outstanding. The number of shares has increased by 129.43% in one year.
Shares Outstanding | 2.68M |
Shares Change (YoY) | 129.43% |
Shares Change (QoQ) | 54.93% |
Owned by Institutions (%) | 0% |
Shares Floating | 1.15M |
Failed to Deliver (FTD) Shares | 7.84K |
FTD / Avg. Volume | 23.6% |
Short Selling Information
The latest short interest is 62.11K, so 2.32% of the outstanding shares have been sold short.
Short Interest | 62.11K |
Short % of Shares Out | 2.32% |
Short % of Float | 6.65% |
Short Ratio (days to cover) | 0.6 |
Valuation Ratios
The PE ratio is -0.21 and the forward PE ratio is -8.5. Vaccinex's PEG ratio is 0.
PE Ratio | -0.21 |
Forward PE | -8.5 |
PS Ratio | 7.52 |
Forward PS | 0 |
PB Ratio | -1.85 |
P/FCF Ratio | -0.25 |
PEG Ratio | 0 |
Enterprise Valuation
Vaccinex Inc. has an Enterprise Value (EV) of 3.03M.
EV / Earnings | -0.15 |
EV / Sales | 5.31 |
EV / EBITDA | -0.15 |
EV / EBIT | -0.13 |
EV / FCF | -0.18 |
Financial Position
The company has a current ratio of 0.57, with a Debt / Equity ratio of -0.11.
Current Ratio | 0.57 |
Quick Ratio | 0.57 |
Debt / Equity | -0.11 |
Total Debt / Capitalization | -11.97 |
Cash Flow / Debt | -69.77 |
Interest Coverage | -22885 |
Financial Efficiency
Return on equity (ROE) is 8.76% and return on capital (ROIC) is 1108.77%.
Return on Equity (ROE) | 8.76% |
Return on Assets (ROA) | -5.58% |
Return on Capital (ROIC) | 1108.77% |
Revenue Per Employee | $15,405.41 |
Profits Per Employee | $-547,324.32 |
Employee Count | 37 |
Asset Turnover | 0.16 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -87.43% in the last 52 weeks. The beta is 1.31, so Vaccinex's price volatility has been higher than the market average.
Beta | 1.31 |
52-Week Price Change | -87.43% |
50-Day Moving Average | 1.16 |
200-Day Moving Average | 3.96 |
Relative Strength Index (RSI) | 47.41 |
Average Volume (20 Days) | 33.24K |
Income Statement
In the last 12 months, Vaccinex had revenue of 570K and earned -20.25M in profits. Earnings per share was -43.68.
Revenue | 570K |
Gross Profit | 570K |
Operating Income | -22.89M |
Net Income | -20.25M |
EBITDA | -19.75M |
EBIT | -22.89M |
Earnings Per Share (EPS) | -43.68 |
Balance Sheet
The company has 1.53M in cash and 247K in debt, giving a net cash position of 1.29M.
Cash & Cash Equivalents | 1.53M |
Total Debt | 247K |
Net Cash | 1.29M |
Retained Earnings | -339.93M |
Total Assets | 4.85M |
Working Capital | -1.42M |
Cash Flow
In the last 12 months, operating cash flow was -17.23M and capital expenditures -67K, giving a free cash flow of -17.3M.
Operating Cash Flow | -17.23M |
Capital Expenditures | -67K |
Free Cash Flow | -17.3M |
FCF Per Share | -37.31 |
Margins
Gross margin is 100%, with operating and profit margins of -4.01K% and -3.55K%.
Gross Margin | 100% |
Operating Margin | -4.01K% |
Pretax Margin | -3.55K% |
Profit Margin | -3.55K% |
EBITDA Margin | -3.46K% |
EBIT Margin | -4.01K% |
FCF Margin | -3.04K% |
Dividends & Yields
VCNX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -3970.91% |
FCF Yield | -587.61% |
Analyst Forecast
Currently there are no analyst rating for VCNX.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 20, 2024. It was a backward split with a ratio of 1:14.
Last Split Date | Feb 20, 2024 |
Split Type | backward |
Split Ratio | 1:14 |
Scores
Altman Z-Score | -115.15 |
Piotroski F-Score | 4 |